Faes Farma SA - Asset Resilience Ratio
Faes Farma SA (FAE) has an Asset Resilience Ratio of 0.95% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check FAE strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Faes Farma SA's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Faes Farma SA to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Faes Farma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Faes Farma SA (FAE) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €12.78 Million | 0.95% |
| Total Liquid Assets | €12.78 Million | 0.95% |
Asset Resilience Insights
- Limited Liquidity: Faes Farma SA maintains only 0.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Faes Farma SA Industry Peers by Asset Resilience Ratio
Compare Faes Farma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
Haleon plc
NYSE:HLN |
Drug Manufacturers - Specialty & Generic | 4.06% |
|
Viatris Inc
NASDAQ:VTRS |
Drug Manufacturers - Specialty & Generic | 1.62% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Shenzhen Kangtai Biological Products Co Ltd
SHE:300601 |
Drug Manufacturers - Specialty & Generic | 12.24% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
Annual Asset Resilience Ratio for Faes Farma SA (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Faes Farma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.95% | €12.78 Million ≈ $14.94 Million |
€1.34 Billion ≈ $1.57 Billion |
+0.02pp |
| 2024-12-31 | 0.93% | €7.92 Million ≈ $9.26 Million |
€853.08 Million ≈ $997.34 Million |
-0.76pp |
| 2023-12-31 | 1.69% | €13.10 Million ≈ $15.32 Million |
€776.03 Million ≈ $907.26 Million |
-9.90pp |
| 2022-12-31 | 11.59% | €84.10 Million ≈ $98.32 Million |
€725.67 Million ≈ $848.38 Million |
+0.15pp |
| 2021-12-31 | 11.44% | €73.41 Million ≈ $85.82 Million |
€641.76 Million ≈ $750.29 Million |
-5.07pp |
| 2020-12-31 | 16.51% | €93.14 Million ≈ $108.89 Million |
€564.15 Million ≈ $659.55 Million |
+16.24pp |
| 2019-12-31 | 0.27% | €1.33 Million ≈ $1.55 Million |
€493.67 Million ≈ $577.16 Million |
+0.19pp |
| 2018-12-31 | 0.08% | €371.00K ≈ $433.74K |
€480.80 Million ≈ $562.11 Million |
+0.06pp |
| 2017-12-31 | 0.02% | €70.00K ≈ $81.84K |
€430.24 Million ≈ $503.00 Million |
-2.15pp |
| 2016-12-31 | 2.17% | €7.18 Million ≈ $8.40 Million |
€331.22 Million ≈ $387.23 Million |
-0.36pp |
| 2015-12-31 | 2.53% | €7.36 Million ≈ $8.60 Million |
€290.68 Million ≈ $339.83 Million |
+0.08pp |
| 2014-12-31 | 2.45% | €6.55 Million ≈ $7.66 Million |
€267.23 Million ≈ $312.42 Million |
+0.10pp |
| 2013-12-31 | 2.35% | €6.71 Million ≈ $7.84 Million |
€285.16 Million ≈ $333.38 Million |
+0.40pp |
| 2012-12-31 | 1.95% | €5.60 Million ≈ $6.55 Million |
€286.84 Million ≈ $335.35 Million |
-0.23pp |
| 2011-12-31 | 2.18% | €6.34 Million ≈ $7.41 Million |
€291.12 Million ≈ $340.35 Million |
-1.26pp |
| 2010-12-31 | 3.44% | €10.22 Million ≈ $11.94 Million |
€297.10 Million ≈ $347.34 Million |
-1.41pp |
| 2009-12-31 | 4.85% | €11.45 Million ≈ $13.39 Million |
€235.97 Million ≈ $275.87 Million |
+1.42pp |
| 2008-12-31 | 3.43% | €9.44 Million ≈ $11.04 Million |
€275.01 Million ≈ $321.52 Million |
-2.24pp |
| 2007-12-31 | 5.67% | €15.45 Million ≈ $18.07 Million |
€272.43 Million ≈ $318.50 Million |
-1.47pp |
| 2006-12-31 | 7.14% | €16.59 Million ≈ $19.39 Million |
€232.43 Million ≈ $271.74 Million |
+0.66pp |
| 2005-12-31 | 6.48% | €13.99 Million ≈ $16.36 Million |
€216.04 Million ≈ $252.58 Million |
-0.67pp |
| 2004-12-31 | 7.15% | €14.25 Million ≈ $16.66 Million |
€199.29 Million ≈ $232.99 Million |
+0.98pp |
| 2003-12-31 | 6.17% | €12.21 Million ≈ $14.28 Million |
€198.01 Million ≈ $231.49 Million |
-4.20pp |
| 2002-12-31 | 10.36% | €18.33 Million ≈ $21.43 Million |
€176.91 Million ≈ $206.83 Million |
-8.59pp |
| 2001-12-31 | 18.95% | €4.66 Billion ≈ $5.45 Billion |
€24.57 Billion ≈ $28.73 Billion |
-1.16pp |
| 2000-12-31 | 20.12% | €4.87 Billion ≈ $5.69 Billion |
€24.21 Billion ≈ $28.30 Billion |
-- |
About Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants servic… Read more